Biogen Inc.

NASDAQ:BIIB

201.44 (USD) • At close September 19, 2024
Bedrijfsnaam Biogen Inc.
Symbool BIIB
Munteenheid USD
Prijs 201.44
Beurswaarde 29,342,153,280
Dividendpercentage 0%
52-weken bereik 189.44 - 269.43
Industrie Drug Manufacturers—General
Sector Healthcare
CEO Mr. Christopher A. Viehbacher
Website https://www.biogen.com

An error occurred while fetching data.

Over Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for

Vergelijkbare Aandelen

DexCom, Inc. logo

DexCom, Inc.

DXCM

71.92 USD

IDEXX Laboratories, Inc. logo

IDEXX Laboratories, Inc.

IDXX

517.06 USD

Royalty Pharma plc logo

Royalty Pharma plc

RPRX

27.99 USD

Seagen Inc. logo

Seagen Inc.

SGEN

228.74 USD

Walgreens Boots Alliance, Inc. logo

Walgreens Boots Alliance, Inc.

WBA

8.98 USD

Align Technology, Inc. logo

Align Technology, Inc.

ALGN

257.17 USD

Illumina, Inc. logo

Illumina, Inc.

ILMN

134.39 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)